Pfizer has acquired 50% stake in IGNITE Immunotherapy. Pursuant to the acquisition, Pfizer will hold 50% equity investment in IGNITE and be responsible for providing research and development funding for three years.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The acquisition will allow Pfizer to develop a new research programme to discover novel vaccinia viruses and also to expand its presence in the immuno-oncology field.

KDB Capital has acquired 6.7% stake in Anygen.

The acquirer is a financial services provider company, while the target is a peptide synthesis provider.

Image: Pfizer has acquired 50% stake in IGNITE Immunotherapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now